| Literature DB >> 35291367 |
Rohini Kalagouda Patil1, Beatrice Kabera2, Charles Kiilu Muia3, Boni Maxime Ale4.
Abstract
Introduction: Hospital acquired infections (HAI) or infections acquired in a hospital setting significantly increase morbidity and mortality, prolong hospital stay and increase healthcare costs. Factors like malnutrition and irrational use of antibiotics in a resource limited setting contribute to poor outcome in children. Thus a retrospective cross-sectional study was undertaken to study the different types of HAI in children, the different organisms causing them and their sensitivity to different antimicrobials so as to inform appropriate empirical antimicrobial therapy initiation and thus prevent antimicrobial resistance in the region.Entities:
Keywords: Hospital acquired infections; antimicrobial resistance; children; nosocomial infections
Mesh:
Year: 2022 PMID: 35291367 PMCID: PMC8895558 DOI: 10.11604/pamj.2022.41.28.25820
Source DB: PubMed Journal: Pan Afr Med J
demographic characteristics and clinical outcomes of study participants, recruited at Gertrude's Children's Hospital in Nairobi (Kenya), from January 2015 to December 2016 (N=41)
| Characteristics | Number | % |
|---|---|---|
| Gender | ||
| Female | 19 | 46.3 |
| Male | 23 | 56.0 |
| Case fatality rate | 6 | 14.6 |
| Immuno compromised | 1 | 2.4 |
| Prior antibiotic use | 35 | 85.3 |
| Invasive device | 23 | 56.0 |
| Multi-organ involvement | 22 | 53.6 |
| Transfusion | 23 | 56.0 |
| Protein energy malnutrition | ||
| Grade I | 1 | 2.4 |
| Grade II | 5 | 12.1 |
| Grade III | 36 | 87.8 |
| Median (IQR) duration of antibiotic (days) | 14(7-21) | |
| Median (IQR) duration of hospitalization (days) | 18 (7-42) | |
| Median (IQR) age (days) | 716 (153-1460) |
Figure 1spectrum of organisms causing specific hospital acquired infections in study participants, recruited at Gertrude's Children’s Hospital in Nairobi (Kenya), from January 2015 to December 2016
antibiotic sensitivity patterns in gram negative organisms of study participants, recruited at Gertrude's Children's Hospital in Nairobi (Kenya), from January 2015 to December 2016
| Organism | total tested | type | gentamycin | trimethoprim/sulfamethoxazole | amoxicillin/clavulanic acid | cefuroxime | cefotaxime | ceftriaxone | ceftazidime | amikacin | ciprofloxacin | meropenem | cefepime | piperacillin | piperacillin /tazobactum | nitrofurantoin | ampicillin sulbactum | ampicillin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 13 | nR | 7 | 7 | 6 | 8 | 8 | 5 | 2 | 1 | 2 | 2 | 1 | 0 | 3 | 1 | 0 | 0 |
| %R | 53.8 | 53.8 | 46.2 | 61.5* | 61.5* | 38.5* | 15.4* | 7.7* | 15.4* | 15.4* | 7.7* | 0 | 23.1* | 7.7* | 0 | 0 | ||
| nS | 4 | 6 | 6 | 4 | 4 | 0 | 0 | 8 | 10 | 8 | 0 | 0 | 2 | 2 | 0 | 0 | ||
| %S | 30.8 | 46.2 | 46.2 | 30.8 | 30.8 | 0 | 0 | 61.5*** | 76.9*** | 61.5*** | 0 | 0 | 15.4*** | 15.4** | 0 | 0 | ||
|
| 5 | nR | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| %R | 0 | 0 | 0 | 0 | 60* | 60* | 0 | 0 | 0 | 0 | 20* | 0 | 20* | 0 | 0 | 0 | ||
| nS | 5 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 5 | 5 | 4 | 0 | 4 | 0 | 0 | 0 | ||
| %S | 100 | 0 | 0 | 0 | 0 | 0 | 60 | 100 | 100 | 100 | 80 | 0 | 80 | 0 | 0 | 0 | ||
|
| 1 | nR | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| %R | 0 | 100* | 100* | 0 | 100* | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100* | ||
| nS | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||
| %S | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 0 | 0 | ||
|
| 2 | nR | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| %R | 50 | 100 | 50 | 100 | 50 | 50 | 50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| nS | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | ||
| %S | 50 | 0 | 0 | 0 | 50 | 0 | 50 | 100 | 100 | 100 | 50 | 50 | 0 | 0 | 0 | 0 | ||
|
| 1 | nR | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| %R | 100* | 0 | 0 | 100* | 100* | 100* | 100* | 0 | 100* | 0 | 0 | 0 | 100* | 0 | 100* | 0 | ||
| nS | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| %S | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Resistance; ** Gram negative organism; *** Sensitivity
antibiotic sensitivity patterns in gram positive organisms of study participants, recruited at Gertrude's Children's Hospital in Nairobi (Kenya), from January 2015 to December 2016
| Organism | total tested | type | penicillin | ampicillin | cloxacillin | eythromycin | gentamycin | clindamycin | trimethoprim/sulfamethoxazole | cefotaxime | ceftriaxone | vancomycin | cefuroxime | ceftazidime | cefepime | piperacillin | ciprofloxacin | amikacin | meropenem |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 2 | nR | 2 | 2 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| %R | 100* | 100* | 0 | 50 | 0 | 50* | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| nS | 0 | 0 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| %S | 0 | 0 | 100 | 50 | 100 | 50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
|
| 1 | nR | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| %R | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| nS | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| %S | 0 | 0 | 0 | 0 | 0 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Resistance; ** Gram positive organism